Cardiac troponins (cTn) are the preferred biomarkers for the detection of myocardial injury and the diagnosis of myocardial infarction (MI) [1–3]. However, with the advent of high-sensitivity (hs)-cTn assays, elevated levels of cTn may be a common finding in daily clinical practice even in several non-ischaemic, acute or chronic conditions, such as heart failure (HF), chronic kidney disease (CKD), sepsis, inflammatory diseases, etc. [4–10].
